A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 329 participants.
Also called NCT01717313
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 329 participants
- Sponsor
- Registry
-
NCT01717313 -
2012-003626-24
-
- Other papers using this trial's data
- A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01717313. Randomized; triple masking; primary purpose treatment. Start 2012-12-05 (actual); primary completion 2015-06-19 (actual). Results posted on 2016-07-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Omarigliptin
- Intervention (Drug)
- Placebo to Omarigliptin
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Placebo to metformin
- Intervention (Drug)
- Glimepiride
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01717313- Content hash
525254eaf3bcbe289abc2b5b886e040d611e4a42ce92d72ffaa17ef734dd3a83